MedTrace Logo

RICE: Remission by Intra-articular Injection Plus CErtolizumab

NCT02293590 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2018-08-03

No results posted yet for this study

Summary

Tight control of an adaptive concomitant treatment strategy after initiation of CZP will lead to an improved outcome of RA patients with an active disease despite DMARD treatment.

Conditions

Interventions

DRUG

Certolizumab Pegol

Sponsors & Collaborators

  • UCB Pharma

    collaborator INDUSTRY

  • Rüdiger B. Müller

    lead OTHER

Principal Investigators

  • Rueediger B Mueller, MD · Cantonal Hospital of St. Gallen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2017-12-22
Completion
2018-01-15

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02293590 on ClinicalTrials.gov